URL | https://bioprocessintl.com/bioprocess-insider/faci |
Source | Bio Process International |
Date Published | 04/28/2022 |
Mentions specific company case(s) of reshoring, kept from offshoring, or transplant | Yes |
Company/Division name | Genezen |
Type of work | Manufacturing |
Reshoring category: | Reshoring |
Year reshoring announced: | 2022 |
Domestically, the work will be done: | In-house |
City reshored to: | Indianapolis |
State(s) reshored to: | IN |
If relevant, work nearshored to: | - |
Industry(ies): | Chemicals |
Product(s) reshored | gene therapy CDMO |
What domestic positive factors made reshoring more attractive? | Lead time/Time to market |